Show simple item record

dc.contributor.authorBowyer, S
dc.contributor.authorPrithviraj, P
dc.contributor.authorLorigan, Paul C
dc.contributor.authorLarkin, J
dc.contributor.authorMcArthur, G
dc.contributor.authorAtkinson, V
dc.contributor.authorMillward, M
dc.contributor.authorKhou, M
dc.contributor.authorDiem, S
dc.contributor.authorRamanujam, S
dc.contributor.authorKong, B
dc.contributor.authorLiniker, E
dc.contributor.authorGuminski, A
dc.contributor.authorParente, P
dc.contributor.authorAndrews, M
dc.contributor.authorParakh, S
dc.contributor.authorCebon, J
dc.contributor.authorLong, G
dc.contributor.authorCarlino, M
dc.contributor.authorKlein, O
dc.date.accessioned2017-05-02T20:23:40Z
dc.date.available2017-05-02T20:23:40Z
dc.date.issued2017-04-11
dc.identifier.citationReply to 'Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. 2017, 116(8):e15 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid28324885
dc.identifier.doi10.1038/bjc.2017.59
dc.identifier.urihttp://hdl.handle.net/10541/620321
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleReply to 'Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.en
dc.typeArticleen
dc.contributor.departmentRockingham General Hospital, Perth, Western Australia, Australiaen
dc.identifier.journalBritish Journal of Canceren


This item appears in the following Collection(s)

Show simple item record